on CARMAT (EPA:ALCAR)
Judicial recovery procedure at CARMAT: update
CARMAT, the company that designs the Aeson® artificial heart, has announced that it will suspend its stock price from August 14, 2025, ahead of a crucial hearing scheduled for August 19. CARMAT, which has been in receivership proceedings since July 1, 2025, received a takeover bid on July 31. This bid will be reviewed by the Versailles Economic Activities Court.
Validation of this offer is not guaranteed, and even if it were accepted, investors and creditors could suffer substantial losses. At the same time, CARMAT continues to support patients benefiting from the Aeson® artificial heart.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CARMAT news